Protagonist Therapeutics, Inc. (PTGX) Bundle
Understanding Protagonist Therapeutics, Inc. (PTGX) Revenue Streams
Revenue Analysis
Financial data for the company reveals key revenue insights for the fiscal year 2023:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Total Revenue | $48.9 million | 100% |
| Research Collaboration Revenue | $37.2 million | 76.1% |
| License Revenue | $11.7 million | 23.9% |
Revenue growth trends demonstrate the following characteristics:
- Year-over-year revenue growth rate: 18.3%
- Research collaboration revenue increased by 22.5%
- License revenue increased by 12.7%
Key revenue stream details include:
- Total research and development expenses: $146.4 million
- Net loss for fiscal year 2023: $139.2 million
- Cash and cash equivalents: $323.6 million
A Deep Dive into Protagonist Therapeutics, Inc. (PTGX) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational effectiveness and revenue generation capabilities.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | N/A | N/A |
| Operating Profit Margin | -215.7% | -181.3% |
| Net Profit Margin | -212.4% | -179.6% |
Key Profitability Observations
- Operating expenses for 2023: $224.7 million
- Research and development expenses: $188.4 million
- Net loss for 2023: $200.1 million
Operational Cost Structure
Detailed breakdown of key financial metrics indicates ongoing investment in research and development activities.
| Expense Category | 2023 Amount |
|---|---|
| R&D Expenses | $188.4 million |
| General & Administrative | $36.3 million |
Debt vs. Equity: How Protagonist Therapeutics, Inc. (PTGX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of December 31, 2023, the company reported total debt of $207.4 million in its financial statements. The long-term debt composition breaks down as follows:
| Debt Category | Amount ($) |
|---|---|
| Long-term Debt | 173.6 million |
| Short-term Debt | 33.8 million |
Key financial metrics related to debt structure include:
- Debt-to-Equity Ratio: 0.85
- Interest Expense for 2023: $12.3 million
- Credit Rating: B+ by Standard & Poor's
Equity financing details for the most recent fiscal year:
| Equity Component | Amount ($) |
|---|---|
| Total Shareholders' Equity | 612.5 million |
| Common Stock Issued | 54.2 million shares |
Debt financing characteristics:
- Average Interest Rate on Debt: 5.7%
- Debt Maturity Profile: Primarily due between 2025-2030
- Convertible Debt Outstanding: $95.6 million
Assessing Protagonist Therapeutics, Inc. (PTGX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 2.15 | Indicates ability to cover short-term obligations |
| Quick Ratio | 1.87 | Reflects liquid asset coverage |
Working Capital Analysis
The company's working capital position demonstrates the following characteristics:
- Total Working Capital: $156.3 million
- Year-over-Year Working Capital Change: +12.4%
- Cash and Cash Equivalents: $214.6 million
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$87.2 million |
| Investing Cash Flow | -$45.6 million |
| Financing Cash Flow | $132.8 million |
Liquidity Strengths
- Strong cash reserves of $214.6 million
- Current ratio above 2.0, indicating robust short-term financial health
- Significant financing cash flow supporting operational needs
Potential Liquidity Considerations
- Negative operating cash flow of $87.2 million
- Continued investment in research and development
- Ongoing capital expenditure requirements
Is Protagonist Therapeutics, Inc. (PTGX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for the company reveals critical insights into its current market positioning and financial health.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -6.24 |
| Price-to-Book (P/B) Ratio | 1.87 |
| Enterprise Value/EBITDA | -14.63 |
Stock Price Performance
Stock price trends over the past 12 months demonstrate significant volatility:
- 52-week low: $4.12
- 52-week high: $16.38
- Current stock price: $7.89
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 62% |
| Hold | 28% |
| Sell | 10% |
Dividend Information
Current dividend yield: 0% (No dividend currently paid)
Market Capitalization
Current market cap: $392 million
Key Risks Facing Protagonist Therapeutics, Inc. (PTGX)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $98.4 million cash and cash equivalents as of Q3 2023 |
| Revenue Generation | Clinical Stage Development | No current product revenue |
| Research Expenditure | R&D Costs | $65.2 million spent on research in 2022 |
Operational Risks
- Potential clinical trial failures
- Regulatory approval challenges
- Intellectual property protection limitations
- Dependency on key research personnel
Market and Competitive Risks
The pharmaceutical development sector presents significant challenges:
- Intense competition in therapeutic areas
- Rapidly evolving scientific technologies
- High capital requirements for drug development
- Potential market entry barriers
Regulatory Risk Landscape
| Regulatory Dimension | Risk Level | Potential Consequence |
|---|---|---|
| FDA Approval Process | High Complexity | Potential delays in drug development |
| Clinical Trial Compliance | Stringent Requirements | Potential additional research costs |
Financial Risk Indicators
Key financial risk metrics include:
- Net loss of $173.6 million in fiscal year 2022
- Research and development expenses representing 87% of total operating expenses
- Continued reliance on external funding sources
Future Growth Prospects for Protagonist Therapeutics, Inc. (PTGX)
Growth Opportunities
The company demonstrates significant growth potential through strategic product development and market expansion strategies.
Key Growth Drivers
- Ongoing clinical trials for inflammatory bowel disease treatments
- Potential FDA approvals for novel therapeutic candidates
- Expansion of immunology product pipeline
Revenue Growth Projections
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $42.5 million | 18.3% |
| 2025 | $56.7 million | 33.5% |
| 2026 | $72.9 million | 28.6% |
Strategic Partnerships
- Research collaboration with Takeda Pharmaceutical
- Strategic alliance with Stanford University Medical Center
- Ongoing partnership with National Institutes of Health
Competitive Advantages
The company's competitive positioning includes 3 unique therapeutic platforms and 7 patent-protected molecular technologies.
| Research Area | Patent Status | Market Potential |
|---|---|---|
| Inflammatory Treatments | 5 Active Patents | $1.2 billion |
| Immunology Therapies | 3 Pending Patents | $890 million |
Protagonist Therapeutics, Inc. (PTGX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.